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ABSTRACT 
Objectives: This study examines how the perceived role of poor lifestyle and irresponsible 
behaviour in contracting HIV, HPV, and diabetes affects public support for government-
provisioned prevention efforts in Britain. It assesses whether public attitudes on healthcare 
spending are broadly sensitive to ‘lifestyle stigmas.’ 
 
Methods: We conducted an online survey of 738 respondents in Britain and embedded 
three separate survey experiments to measure support for government-provisioned 
interventions for HIV, HPV, and type 2 diabetes. In each experiment, we manipulated 
language used to describe the extent to which the diseases are caused by lifestyle choices. 
Most respondents participated in all three experiments, but assignment was randomized 
within each condition. Analysis compared support amongst respondents exposed to 
‘lifestyle’ treatment (information emphasising the disease’s lifestyle causes) versus control 
treatment. We estimated three separate t-tests in which support for government provision 
of interventions is the dependent variable. 
 
Results: Support for government-provisioned prevention was high for all three diseases. 
There was no statistical difference between treatment and control conditions for HIV 
(treatment mean = 3.73, control mean = 3.86, p=0.38). But in both HPV (treatment mean = 
3.96, control mean = 4.43, p<0.01) and type 2 diabetes (treatment mean = 3.53, control 
mean = 4.03, p<0.01) experiments, support for government-provisioned interventions was 
significantly lower under lifestyle treatment conditions.  
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Conclusions: Public opinion on healthcare expenditures in Britain is unexpected and uneven. 
Consistent participant support for PrEP shows public attitudes are not always sensitive to 
lifestyle stigmas—but for other diseases, perceived relationships between individual 
behaviour and poor health can still shape public opinion about health expenditures. 
Policymakers and practitioners should remain attentive to how health problems are framed 
and discussed to ensure broad public support, but also take advantage of policy windows 
like with PrEP as they may close. 
Strengths and limitations of this study  
 First-of-its-kind survey that measures public awareness and opinion on PrEP in Britain 
 Comparison across multiple diseases to understand where lifestyle stigma does and does not 
operate 
 Survey conducted at height of negative media coverage on PrEP 
 Public opinion on matters related to the NHS can be unstable 
 Online panels are not necessarily representative of the general population 
 Lifestyle treatment in the HIV experiment works slightly differently than in the other 
experiments 
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INTRODUCTION 
Despite trials demonstrating its effectiveness at preventing HIV and research showing its 
long-term cost savings, [1-3] in 2016 NHS England (NHSE) decided to not provide full 
universal access to pre-exposure prophylaxis (PrEP), a daily dose pill of antiretroviral drugs 
taken to lower risk of contracting HIV. While justified by the need for treatment rationing 
amidst broader fears of the National Health Service’s (NHS) long-term sustainability,[4] the 
decision—and a subsequent High Court challenge—occurred in a charged media 
environment. Perceived beneficiaries were effectively put on trial; public provision of PrEP 
was suggested to be tantamount to government endorsement of irresponsible sexual 
behaviour. Most Britons had never heard of PrEP. Yet, media narratives were built upon the 
assumption that taxpayers are averse to giving public funds to those whose health problems 
are seen as resulting from ‘irresponsible behaviour’ and ‘poor lifestyle choices.’[5, 6]  
But does this assumption accurately reflect public attitudes in Britain? Rather than 
simply measuring and reporting public opinion about PrEP, we place it into a broader, 
comparative context. By exploring attitudes on the Human Papilloma Virus (HPV) and type 2 
diabetes, this study aims to answer a larger question, one especially important in countries 
like Britain where publicly-funded healthcare makes health policy more susceptible to public 
opinion: are public attitudes on government expenditures broadly sensitive to a ‘lifestyle 
stigma,' the belief that diseases are due to poor lifestyle or irresponsible behaviour? 
Background 
Beliefs that a lifestyle stigma can drive public opinion and affect government 
expenditure decisions are not unfounded. Responsibilisation attitudes[7]—the idea that 
individuals should take personal responsibility for their own well-being—frequently impact 
public opinion, especially on health matters and those which are newly-emerging [8, 9, 10-
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12]; problems seen as resulting from irresponsible behaviour are less likely to garner 
support for government funding[13].  
While the effect of public opinion on policymaking is the subject of debate, scholars 
estimate that it impacts policy three quarters of the time it is gauged, with substantial effect 
at least one-third of the time.[14]; its effect varies due to issue salience, public knowledge, 
degree of public attitudinal shifts, and political and institutional processes mediating the 
ability of policymakers to respond.[15-19] In liberal democracies, elected officials are 
incentivised to directly respond to public opinion through reform.[16, 20, 21, 22] But 
policymakers do not always have a good understanding of these attitudes. How 
policymakers perceive public opinion is thus especially pertinent and factored into how 
policy is developed.[15, 22, 23]  
The popularity of Britain’s publicly-funded National Health Service (NHS) has meant 
that public opinion is stronger and matters even more for policymakers.[23, 24, 25] With the 
introduction of market-based systems of provision in the 1990s and semi-privatisation in the 
last decade, public opinion is now effectively built into the NHS, bound by a legal 
requirement for ‘public consultation-seeking’ to better the ‘consumer experience.’[25, 26] 
Increased emphasis on personal responsibility in healthcare provision is evident now as 
NHS's future has been seen dependent upon cost-cutting and rationing of care,[27, 28] 
featuring prominently in the EU Referendum.[29] It suggests that the treatment of certain 
diseases seen as the result of poor lifestyle choices and bad behaviour will lack public 
support and could factor into policymaking decisions. This was reflected in the recent case 
of PrEP in Britain. NHSE’s decision to not fund the drug came amidst strong negative media 
coverage: a front-page story in the Daily Mail declared, ‘NHS told to give out £5,000-a-year 
lifestyle drug to prevent HIV—as vital cataract surgery is rationed. What a skewed sense of 
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values.’ Although the general public was not surveyed in advance of the decision, 
policymakers seemed to have been anticipating a negative response.[30-32] 
We know very little about public perception of PrEP anywhere in the world, including 
Britain. Current literature has focused primarily on attitudes towards the drug amongst 
healthcare providers and potential beneficiaries.[33, 34] But even these studies point to a 
lifestyle stigma associated with PrEP use. A survey of healthcare providers in North America 
found moral concerns about ‘bad behaviours’ affects willingness of some providers to 
prescribe the drug.[35, p. 705] Even within gay communities, PrEP is often seen as an overly-
expensive excuse for ‘risk-taking’ gay and bisexual men to continue engaging in 
‘irresponsible’ risky sexual behaviour.[31, 36] Concerns that PrEP offers free license to be 
sexually promiscuous mirrors concerns over antiretroviral medicine in the mid-1990s for 
HIV/AIDS [31] and the oral contraceptive pill in the 1960s.[32]  
While studies allude to a lifestyle stigma around PrEP use,[35] few have explored in-
depth how perceptions of lifestyle affect public support for PrEP provision and use.[37] 
Limited research has examined how certain demographic groups—and prejudices and 
biases associated with them—might disproportionately experience lifestyle stigma in 
relation to PrEP.[30, 31, 34] And while stigmas on some lifestyle-related diseases have been 
compared previously,[38] no previous studies have included attitudes toward PrEP and HIV 
in such comparative analyses. Comparing public perceptions of PrEP and HIV with other 
lifestyle-related diseases can yield important insights about stigma and health policymaking 
more generally. Moreover, while a study of Britain is especially timely due to care rationing 
and growing attitudes of responsibilisation within the general public,[27, 28, 5] insights 
gleaned here could well travel to comparable political contexts facing similar issues.  
The current study 
7 
 
This study compares public opinion of NHS-funded PrEP to prevent HIV with 
attitudes toward publicly-funded treatment for HPV and type 2 diabetes, focusing on how 
perceptions of lifestyle in their acquisition shapes opinion. While the majority of Britons 
believe in government responsibility for healthcare, the public increasingly feels the 
government's role should be weighed against personal responsibility.[5] The majority of 
respondents in a 2014 study disagreed that it should be the UK government's responsibility 
to influence individual behaviour by regulating and taxing high-calorie food and drink, and 
incentivising giving up heavy drinking and losing weight.[39] Lifestyle stigma can differ 
according to perceived causes of disease:[40] people are less likely to help victims of lung 
cancer resulting from smoking for 20 years than those who developed it from working in a 
mine for the same time[41] and less likely to donate money to lung cancer research (seen as 
the result of bad behaviour) than breast cancer research.[42]  
Public attitudes toward health policies can also be influenced by pre-existing stigma 
against those seen as key beneficiaries. Support for policies varies depending on whether 
benefiting groups are perceived positively or negatively.[43, 44] During the AIDS epidemic in 
the US, public stigma towards gay men affected how policymakers subsequently framed 
policies that would entail social benefits to gay men with HIV.[45] Because HIV and HPV are 
both sexually transmitted, we expect this information to negatively affect public opinion of 
publicly provisioned PrEP and the HPV vaccine (currently offered to girls age 12 and 13, and 
soon to boys of the same age). 
Previous studies on HPV suggest the presence of lifestyle stigma in public 
perceptions of the disease:[46, 47] adolescent girls with HPV feared they would be excluded 
if their condition was discovered by others;[48] when told it was an STD, university-aged 
female respondents in the US characterised those with HPV as being ‘dirty, dishonest, and 
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unwise';[49] a study of British women found those who knew cervical cancer was linked to 
sexual activity were significantly more likely to blame the victims, as they viewed the cancer 
as thus the result of irresponsible behaviour.[47] As such, we expect that support for an 
NHS-funded vaccine will be highest when respondents are told that HPV can cause cancer; 
as it gets more closely linked to behaviour and lifestyle support will decrease. 
Similarly, a study of adults with type 2 diabetes found a vast majority of participants 
perceived and experienced lifestyle stigma, feeling blamed for their condition through poor 
health habits.[6, 50] Responsibilisation attitudes are shown to underlie type 2 diabetes 
stigma, where the inability to adhere to healthy dietary habits, exercise, and regular 
professional supervision reflected ‘moral failings’;[6] similar attitudes toward obesity are 
present in Britain[47] and often associated with type 2 diabetes.[6] Other studies have 
explored how framing can affect support for diabetes prevention policies. When diabetes is 
discussed as a consequence of individual behaviour, Republican respondents in a US study 
were more likely to oppose government funding to address it.[51]  
Against this backdrop, we therefore propose an overarching hypothesis: When 
respondents are prompted to think about lifestyle causes of diseases, they are less likely to 
support public provision of drugs to avoid or treat it. While we expect lifestyle stigma to be 
present in all three cases, there are important differences that could affect the strength of 
the stigma on attitudes.  
METHODS 
In order to test our expectations, we fielded a survey of 738 respondents in Britain using a 
panel from Prolific, a service that matches researchers with people willing to do short 
surveys, for small amounts of money. Participants (totally 170,000 as of September 2018) 
are recruited via social media, poster/flyer campaigns, and referrals; they must provide and 
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confirm a phone number and email address in order to participate. For any given study, a 
sample of eligible participants are contacted through the service.  Prolific is comparable to 
Amazon’s Mechanical Turk, though research shows it offers a more diverse sample that is 
more naïve and less dishonest.[52, 53] 
Research ethics approval for the survey was granted in September 2016 by the first 
author’s institution; all participants gave informed consent before beginning the survey. 
While the research was done without direct patient or public involvement, the public was 
involved as survey respondents. 
The sample has a distribution that is roughly analogous to that of the target 
population (adults in the UK), in terms of age (22.3% 18-24, 34.4% 25-34, 20.9% 35-44, 
14.1% 45-54, 6.4% 55-64, 1.8% 65 or older), gender (40.7% male, 58.8% female, .6% other 
or prefer not to say), race and ethnicity (87.4% white, 2.4% mixed race, 6.4% Asian/Asian 
British, 2.8% Black/African Caribbean/Black British, 1.2% other ethnic group), and political 
ideology (24.5% conservative, 28.3% moderate, 47.2% liberal). 
Within this survey, we embedded three separate survey experiments. Most 
respondents participated in each of the three experiments, but assignment was randomised 
(automatically through the survey software) within each condition. Therefore, assignment 
to one condition was independent of assignment to any other condition.  
The first focused on attitudes towards PrEP, varying what group PrEP was described 
as targeting in a clinical trial. Participants were told, ‘PrEP is a drug used to protect against 
exposure to the HIV virus. In a recent study of approximately 500 [target group], this drug 
was shown to be almost entirely effective at preventing HIV infection when used as 
directed. Based on this, would you approve or disapprove of the NHS covering the costs of 
PrEP?’ The target group was either ‘people’ for the control condition (N = 115), or ‘people 
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who have frequent sex with multiple partners’ in the lifestyle condition (N = 105). In the full 
experiment, additional group targets were included: ‘gay men,’ ‘gay men who have frequent 
sex with multiple partners,’ ‘high risk gay men,’ ‘pregnant women,’ and ‘non-UK born 
people.’ For a cleaner comparison, we restrict our analyses here to only ‘people’ and 
‘people who have frequent sex with multiple partners,’ in order to focus most clearly on the 
lifestyle element in which we are interested.  
The second survey experiment focused on HPV. This experiment allows us to gauge 
whether elicitation of sympathy or perceptions of innocence change when prompted to 
think about sexual behaviour. Respondents therefore received one of two versions of the 
question, one where they are told that HPV is a sexually-transmitted disease (STD) that can 
cause cervical cancer, and a control where they are not told it is sexually transmitted. We 
asked participants, ‘HPV, or “human papilloma virus”, can cause cervical cancer in women. 
Do you approve of the NHS funding of the HPV vaccine for all girls age 12 to 13?’ in the 
control condition (N = 241), and ‘HPV, or, the “human papilloma virus,” is a common 
sexually transmitted disease in women. Do you approve of the NHS covering the cost of the 
HPV vaccine for all girls age 12 to 13?’  in the lifestyle condition (N = 255). Again, there was 
one omitted condition for this survey experiment, which combined the treatment and 
control, mentioning both cancer and that HPV is a sexually transmitted disease.  
However, questions and experiments on HIV and HPV might also be affected by anti-
gay biases or sexual moralising. Thus, to disentangle the conversation from sex and sexual 
identity we included a third survey experiment on type 2 diabetes. In the survey we ask 
about support for a hypothetical drug to prevent type 2 diabetes, while either including or 
excluding information about type 2 diabetes being associated with unhealthy lifestyle 
causes. We asked respondents ‘Would you approve of NHS covering the cost of a drug that 
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could effectively prevent type 2 diabetes’ in the control condition (N = 367), and ‘Would you 
approve of NHS covering the cost of a drug that could effectively prevent type 2 diabetes, 
which is often associated with unhealthy eating and inactive lifestyles?’ in the lifestyle 
condition (N = 356).  
Our analysis compares respondents who are exposed to a ‘lifestyle’ treatment versus 
a control treatment. To consider these potential differences, we estimate three separate t-
tests, with support for the funding of disease prevention as the dependent variable in each 
case. Each of these tests is reported in Table 1.   
Patient and Public involvement  
There was no patient or public involvement in this study. 
RESULTS 
Overall, support for prevention is high in each case. On a scale of 1 to 5 where 5 indicates 
greatest support, respondents in our sample across all conditions are well above the 
midpoint for support of HPV prevention (mean = 4.21, SD = 1.07), diabetes (mean = 3.78, SD 
= 1.11), and HIV (mean = 3.80, SD = 1.08) (see Figure 1). HPV prevention support is 
significantly higher than both support for HIV prevention (t= 8.22, p=0.01) and support for 
diabetes prevention (t= 10.33, p=0.01). Support for HIV prevention and for diabetes 
prevention is not statistically different (t= 0.42, p=0.68). 
 
 
 [FIGURE 1 ABOUT HERE] 
 
 
 
12 
 
Table 1: T-tests estimating support for funding prevention of PrEP, diabetes, and HPV  
 HIV Diabetes HPV 
Lifestyle 3.73 (1.09) 3.53 (1.08) 3.96 (1.18) 
Control 3.86 (1.07) 4.03 (1.09) 4.43 (0.90) 
T statistic  
(significance) 
0.88 (0.38) 6.22 (0.01)* 4.80 (0.01)* 
n 220 723 466 
Means reported in first two rows, with standard deviation in parentheses. Note that n’s are 
different for each test due to different numbers of conditions.   
* p<0.01 
 
 
 Overall, we find what we refer to as lifestyle stigma—effects of reminding 
participants of the lifestyle element of each of the three diseases we consider—for two of 
the three experiments (see Table 1 for test statistics).  
 In the case of diabetes, respondents are roughly half a point less supportive of 
funding prevention efforts when reminded of the lifestyle component of the disease 
(‘unhealthy eating and inactive lifestyles’) than when they are not (lifestyle mean = 3.53, 
control mean = 4.03, p<0.01).  
 When considering support of HPV prevention efforts, findings are similar, with 
respondents about half a point less supportive of funding prevention efforts when reminded 
that HPV is a sexually transmitted disease as compared to when that information is absent 
(lifestyle mean = 3.96, control mean = 4.43, p<0.01). Interestingly, we see an identical 
pattern, though at a lower level of support, when we ask about support for funding HPV 
prevention for boys. Mean support is lower compared to that of girls (4.08 versus 4.24, 
p<.01 when testing difference of means), and the pattern of support by condition mirrors 
that reported above – support is lower when sexual transmission is mentioned (p<.01).  
 When looking at support for HIV prevention, however, the pattern changes. 
Specifically, we see no statistical difference between those who are reminded of lifestyle 
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factors related to contracting HIV (‘people who have frequent sex with multiple partners’) as 
compared to those who do not (lifestyle mean = 3.73, control mean = 3.86, p=0.38). 
Notably, we have a lower n for this test (a total of 220 compared to 723 for diabetes and 
466 for HPV) but should still have sufficient power to detect differences if they exist.  
DISCUSSION 
Results from the experiments suggest the relationship between lifestyle stigma and public 
attitudes on government healthcare expenditures is not clear-cut. Respondents who were 
asked about support for funding the HPV vaccine and told that it was a sexually transmitted 
disease were less likely to support it than those who were not. We found similar patterns 
with type 2 diabetes when respondents were given questions with additional information 
about its behavioural causes. But, surprisingly, we found no evidence of a lifestyle stigma in 
the experiment on HIV and PrEP. Thus, we do not have support across all three cases for our 
hypothesis that attitudes on public healthcare expenditures would sour when primed to 
think about the lifestyle causes of certain diseases. Therefore, we cannot say that public 
attitudes are broadly affected by the perception that those treatments are for diseases seen 
as being the result of poor lifestyle or irresponsible behaviour.  
Our findings corroborate earlier research on British attitudes on care rationing, 
which similarly revealed diverse public preferences.[28] They further complicate and fill a 
major gap in earlier PrEP literature which found stigma towards PrEP use/provision in 
provider and some beneficiary communities,[31, 35, 36] but which—with few exceptions 
[30]—has so far not examined whether such lifestyle stigma affects general public support 
for PrEP (and specifically publicly-provisioned PrEP).  
Given shifts toward responsibilisation in healthcare, diminished resources, and the 
strongly negative media narrative surrounding HIV and PrEP when the survey was 
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conducted, what might explain our divergent findings on lifestyle stigma? Specifically, what 
explanation can we offer for why we saw no ‘lifestyle’ priming difference for HIV? One 
possibility relates to knowledge. Perhaps people know enough about HIV to know that it is a 
sexually transmitted disease.[54, 55] For that reason, they are effectively thinking about it 
as a lifestyle disease whether the framing of the question prompts that or not. So even 
when we do not mention that HIV is sexually transmitted, that is a salient element of what 
people know about the disease, and therefore already top-of-mind.[56]  This would explain 
why we see effects for HPV—where people are less knowledgeable about how the disease 
spreads [57]—but not for HIV.  
Alternatively, drawing upon stigma literature,[40-42, 47, 58] we suggest an 
additional possible explanation: public attitudes of personal responsibility can be mitigated 
by perceptions of disease fatality and incurability, whether seen as the result of a one-time 
indiscretion or the long-term accumulation of bad behaviour.[58-60] Public perceptions of 
contracting HIV are often circumscribed by notions of blame and personal responsibility,[47, 
55, 60] as the recent media coverage over NHS funding of PrEP suggested.[4] Yet, we found 
broad support for public-provisioned PrEP (and for public funding of prevention of HPV and 
diabetes). This echoes findings elsewhere [58] showing that because people perceive HIV to 
be life-threatening, they attach less importance to the stigma associated with how it was 
acquired. This could explain why support for PrEP was unaffected by lifestyle stigma; 
sympathy (or pity) for a 'fatal' illness could outweigh blame for how they contracted the 
disease via perceived 'risky' lifestyle behaviours.  
The presence of a lifestyle stigma was statistically significant for public support of an 
NHS-funded HPV vaccine: we found that support was higher in the control condition where 
HPV was said to cause cervical cancer but no links to sexual lifestyle were mentioned. This is 
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consistent with previous research on HPV, which shows that knowledge of it being sexually 
transmitted can activate stigma against victims, and a tendency to blame the victim [46, 47].   
However, it is possible that public support for PrEP and the HPV vaccine is also 
driven by fear. Diseases perceived as life-threatening can often cause healthy individuals to 
feel particularly vulnerable.[59, 58] Persistent beliefs that those infected lead ‘lonely, hard, 
and isolated lives’ cause some to take overly-cautious, even irrational measures to guard 
against HIV transmission.[55; 61] The incurability of HPV underlies public fear around it as 
well.[46] Thus, fears of communicability, concerns of their own vulnerability, and the drive 
for self-preservation could increase support for public provision of PrEP and the HPV vaccine 
regardless of personal prejudice.  
By contrast, we found that type 2 diabetes received low support for publicly-funded 
interventions and demonstrated the strongest example of lifestyle stigma. This may be due 
to the prevalence of diabetes-related stigma,[6, 50] which is often linked with obesity-
related stigma.[6] Whereas contracting HIV and HPV might be perceived as the result of a 
‘youthful indiscretion’ or a single ‘fateful mistake’, type 2 diabetes is seen as the long-term 
accumulation of poor lifestyle choices. A chronic disease, type 2 diabetes is also widely 
understood to be manageable and potentially reversible with strict diet, exercise, and 
monitoring[62, 63]—the implication being that those who are unable to do so bear full 
responsibility for their disease.[6] Family support for people with diabetes has been found 
to decline over the long-term, while people with HIV experience greater family support than 
those with diabetes.[38] Recent US public attitudes research speaks to our lifestyle stigma 
finding around diabetes, showing worsening negative bias towards body weight/obesity, 
which the study authors note is a target of moral judgment due to perceived 
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controllability.[64] The strong lifestyle stigma could also be explained by race-based and 
class-based prejudice associated with type 2 diabetes.[6, 62] 
Both where we see evidence of a lifestyle stigma in public support (HPV and type 2 
diabetes) and where we do not (HIV), attitudes are likely shaped by many factors, including 
pre-existing perceptions and beliefs about disease fatality and acquisition (whether accurate 
or not). Studies on mass opinion show people are more likely to resist messages when those 
messages contradict their pre-existing worldviews.[56] Likewise, what we might be seeing in 
our study is the dominance of pre-existing worldviews on HIV, HPV, and type 2 diabetes and 
how they can affect public support for health policies.  
LIMITATIONS 
It is important to note that surveys do not always provide an accurate picture of public 
opinion. Results can vary by how, and when, public opinion is measured.[14, 25, 65-67] On 
matters concerning the NHS, public opinion can be volatile and unstable.[25] Because 
surveys are never conducted in a political vacuum, fast-changing media coverage can 
influence respondents, resulting in differing responses even when questions are identically 
worded.[25, 65] Moreover, respondents from online panels such as Prolific are not 
representative of a more general population, so results should be interpreted cautiously. 
While we employed survey experiments to minimise potential biases, some caution is still 
required when comparing the three experiments, particularly because the HIV experiment 
tests behaviour and lifestyle somewhat differently than those on HPV and type 2 diabetes. 
While these are weaknesses of our study, we also point out a key strength: The survey was 
conducted when the media narrative on HIV and PrEP was especially sustained and 
negative—‘easy test’ conditions wherein attitudes should have most strongly affected by 
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biases. Thus, we believe our findings of no lifestyle stigma in the PrEP experiment to be 
especially robust.  
CONCLUSION 
Despite finding broad participant support for PrEP in the case of HIV, results from the two 
experiments demonstrate that public opinion on health expenditures is not immune from 
lifestyle stigma. When framed in certain ways, Britons remain sensitive to the relationship 
between lifestyle behaviours and poor health. We explain this difference primarily by 
suggesting that pre-conceived (mis)understandings of the three diseases drive support up in 
some cases (HIV), and down in others (HPV, type 2 diabetes).  
Regardless of how variation across the experiments is explained, our study contains 
important implications for health policymakers and practitioners. Support for publicly-
provisioned treatments was quite high for all three diseases. But attitudes on healthcare 
expenditures are more complex than anticipated. Participant support for PrEP—where we 
had expected the greatest lifestyle stigma—is unlikely reflective of a broader shift in 
attitudes toward other diseases attributed to poor lifestyle. Yet, on the flip side, this 
presents a policy window[68] for PrEP: if policymakers seek to take advantage of an 
approving public, then this is all the more reason to do it urgently while public support for 
government-provisioned PrEP is still high.  
However, the way health problems are discussed and framed continues to affect 
public attitudes on how—and if—the government should cover the costs to address them. 
But this is also dependent on other factors, which makes the job of health policymakers and 
practitioners all the more difficult. This is particularly relevant in political contexts like 
Britain where publicly-funded healthcare makes health policy more susceptible to public 
opinion—and simultaneously public opinion places a growing emphasis on the role of 
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personal responsibility in individual health.[23, 25-28, 5, 7] Ultimately—and challengingly—
the unexpected and uneven pattern of public attitudes on healthcare expenditures requires 
greater savviness and attentiveness in responding to media narratives and taxpayers’ views.  
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FIGURE LEGEND 
Figure 1: Mean support for public funding of disease prevention by experimental condition. 
Data are shown from 2016 survey of 738 respondents in Britain that demonstrate mean 
levels of support for publicly-funded preventions for HIV, type 2 diabetes, and HPV. Values 
are on a scale of 1 to 5 where 1 is ‘strongly disapprove’ and 5 is ‘strong approve’. The blue 
bar indicates mean level of support for the lifestyle treatment in the survey experiment, 
while the orange bar represents the mean level of support for the control 
